

## SSI Strategy, a portfolio company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand into the EU



Amidst increasing regulatory scrutiny in the drug development industry, the demand for regulatory affairs consulting services has surged. The risks of misalignment with regulatory agency expectations and suboptimal clinical trial design highlight the critical need for proactive solutions, as lack of early planning can lead to delays, additional trials, increased costs, and potential program failure late in development. Regulatory affairs consultants play a pivotal role, offering expert guidance to ensure adherence to ever-changing drug regulations and mitigate risks. As pharmaceutical companies face complex challenges, professional assistance becomes imperative to navigate the evolving regulatory landscape successfully.

Founded in 1997, NDA Group AB ("NDA") is regulatory affairs and drug development

consultancy firm with unmatched regulatory expertise, ensuring the optimal development of complex and innovative treatments to meet strict regulatory agency requirements. Over the past three years, NDA has supported a quarter of the new medicinal products approved in the US and Europe.

NDA's impressive capabilities made it a natural strategic partner for SSI Strategy ("SSI") to join forces with, combining strengths to expand regulatory affairs consulting offerings, grow their foothold in the US, and extend into the EU. Crosstree's comprehensive knowledge of the pharmaceutical regulatory affairs consulting industry assisted SSI in evaluating a diverse set of potential strategic options and identified NDA as the ideal fit for their strategic objectives.

**Crosstree helps clients reach their strategic goals by identifying optimal transaction partners to accelerate growth and enhance value for all stakeholders.**

## ABOUT SSI STRATEGY



SSI Strategy combines business acumen, medical, clinical and pharmacovigilance domain expertise, and operating experience to provide unparalleled support to their clients. Their staff of ex-Chief Medical Officers and former Heads of Medical Affairs, Clinical Development and Safety will work to ensure the right balance of medical and business focus to drive unparalleled outcomes for clients. SSI Strategy is headquartered in Parsippany, NJ, with offices in Boston, London, New York, and San Francisco.

SSI Strategy is a portfolio company of Amulet Capital Partners

## ABOUT NDA GROUP AB



NDA Group is a world-leading regulatory and drug development consultancy company, with 25 years of unparalleled expertise and an extensive portfolio of services through all phases of drug development. Their dedicated team of over 150 consultants combined with the unique NDA Advisory Board provide drug developers with unmatched regulatory expertise, ensuring the optimal development of complex & innovative treatments that meet the rigorous requirements of the regulatory agencies.

## CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

## MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



**GORDON RYERSON**

Co-Founder and Managing Director

[gordon.ryerson@crosstreecapital.com](mailto:gordon.ryerson@crosstreecapital.com)

813-774-4752